The deal will buy Pfizer some additional breathing room, as we had expected sales and earnings per share growth to slow based on the maturing portfolio of drugs, patent expirations in 2004 through 2007, winding down on synergies from the Warner-Lambert merger and weak new product flow. |
You just can't put aside that these companies have been rivals for many years. At some point, you will get a stronger entity than either company is on its own, but execution is key. |